Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry
0301 basic medicine
Cancer Research
Consensus
Monitoring
International Cooperation
Immunology
Tregs
Cell Separation
Lymphocyte Activation
T-Lymphocytes, Regulatory
RC0254
03 medical and health sciences
Antigens, CD
Monitoring, Immunologic
Immunology and Allergy
Animals
Humans
Flow cytometry
Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life Sciences
Cells, Cultured
Ovarian Neoplasms
Forkhead Transcription Factors
Reference Standards
Flow Cytometry
R1
3. Good health
Ki-67 Antigen
Oncology
Phenotyping
QR180
Original Article
Female
Tumor Escape
Biomarkers
DOI:
10.1007/s00262-015-1729-x
Publication Date:
2015-06-27T17:24:56Z
AUTHORS (18)
ABSTRACT
Regulatory T cell (Treg)-mediated immunosuppression is considered a major obstacle for successful cancer immunotherapy. The association between clinical outcome and Tregs is being studied extensively in clinical trials, but unfortunately, no consensus has been reached about (a) the markers and (b) the gating strategy required to define human Tregs in this context, making it difficult to draw final conclusions. Therefore, we have organized an international workshop on the detection and functional testing of Tregs with leading experts in the field, and 40 participants discussing different analyses and the importance of different markers and context in which Tregs were analyzed. This resulted in a rationally composed ranking list of "Treg markers". Subsequently, the proposed Treg markers were tested to get insight into the overlap/differences between the most frequently used Treg definitions and their utility for Treg detection in various human tissues. Here, we conclude that the CD3, CD4, CD25, CD127, and FoxP3 markers are the minimally required markers to define human Treg cells. Staining for Ki67 and CD45RA showed to provide additional information on the activation status of Tregs. The use of markers was validated in a series of PBMC from healthy donors and cancer patients, as well as in tumor-draining lymph nodes and freshly isolated tumors. In conclusion, we propose an essential marker set comprising antibodies to CD3, CD4, CD25, CD127, Foxp3, Ki67, and CD45RA and a corresponding robust gating strategy for the context-dependent analysis of Tregs by flow cytometry.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (54)
CITATIONS (166)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....